ISSN 2590-0048
Vol. 4, Issue 3, 2022August 09, 2022 CDT
High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4+ T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens
High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4+ T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens
Katrine Fladeland Iversen, Line Nederby, Thomas Lund, Torben Plesner,
Articles in Vol. 4, Issue 3, 2022
Vol. 4, Issue 3, 2022
- FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCLCaroline DartigeasBorhane SlamaMargaret DoyleChristoph TapprichClaire AlbrechtSandrine DupuisRobert WapenaarCharlotte Schmidt-HieberVeronique Leblond
- The EBMT Immune Effector Cell Nursing Guidelines on CAR-T Therapy: A Framework for Patient Care and Managing Common ToxicitiesRose EllardMichelle KenyonDaphna HuttErik AertsMaaike de RuijterChristian ChabannonMohamad MohtySilvia MontotoElisabeth WallhultJohn Murray
- Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell TransplantationSayako YudaShigeo FujiBipin SavaniKatie S. Gatwood
- Organizational Challenges in the Pediatric Onco-hematology Units During the First and Second Wave of the COVID-19 Pandemic: A National Survey in ItalyMatteo AmicucciValentina BiagioliElena RostagnoMarta CanesiAnna BergadanoDebora BottaMoreno Crotti Partel
- High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4+ T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing RegimensKatrine Fladeland IversenLine NederbyThomas LundTorben Plesner
- Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United StatesSamer Al HadidiDeepa DongarwarHamisu SalihuCarolina SchinkeSharmilan ThanendrarajanMaurizio ZangariFrits van Rhee
Iversen, Katrine Fladeland, Line Nederby, Thomas Lund, and Torben Plesner. 2022. “High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4+ T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens.” Clinical Hematology International 4 (3): 107–16. https://doi.org/10.1007/s44228-022-00013-7.